The firm is a Private Equity firm that was founded in 2001 and based in Paris, France. The firm controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France. For in-licensing opportunities the firm is willing to look globally.
The firm Is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development.
The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment